Some theoretical models of addictive disorder are used for behavioral transformation

Abstract

Existential, neurobiological and cognitive models of addictive behavior are considered as a theoretical basis for transformational therapy of addictive disorders. The NMDA receptor antagonist ketamine, which has neurotrophic, modulatory and psychedelic effects, demonstrates the universal properties of a transforming agent for any of the presented concepts of addictive behavior. Since persistent mental and behavioral changes essentially are psychobiological changes, the substrate that determines the effectiveness of the intervention is synaptic plasticity and neural network remodeling.

Keywords

addictive disorder / ketamine / synaptic plasticity / network remodeling

References

[1] Kalivas PW, O’Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology. 2008;33:166–180. DOI: 10.1038/sj.npp.1301564.

[2] Kalivas P.W., O’Brien C. Drug addiction as a pathology of staged neuroplasticity // Neuropsychopharmacology. 2008. Vol. 33. P. 166–180. DOI: 10.1038/sj.npp.1301564.

[3] Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162:712–725. DOI: 10.1016/j.cell.2015.07.046

[4] Volkow N.D., Morales M. The brain on drugs: from reward to addiction // Cell. 2015. Vol. 162. P. 712–725. DOI: 10.1016/j.cell.2015.07.046

[5] Jones JL, Mateus CF, Malcolm RJ et al. Efficacy of ketamine in the treatment of substance use disorders: A systematic review. Front Psychiatry. 2018;9:277. DOI: 10.3389/fpsyt.2018.00277.

[6] Jones J.L., Mateus C.F., Malcolm R.J. et al. Efficacy of ketamine in the treatment of substance use disorders: A systematic review // Front. Psychiatry. 2018. Vol. 9. P. 277. DOI: 10.3389/fpsyt.2018.00277.

[7] Kolp E, Friedman HL, Krupitsky E et al. Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology, and clinical applications. International Journal of Transpersonal Studies. 2014;33(2):84–140.

[8] Kolp E., Friedman H.L., Krupitsky E. et al. Ketamine psychedelic psychotherapy: Focus on its pharmacology, pheno-menology, and clinical applications // International Journal of Transpersonal Studies. 2014. Vol. 33. N. 2. P. 84–140.

[9] Krupitskiy EM, Grinenko AYa. Stabilizatsiya remissiy pri alkogolizme (putem ketaminovoy terapii). SPb.: Gippokrat; 1996. 95 р. (In Russ.)

[10] Крупицкий Е.М., Гриненко А.Я. Стабилизация ремиссий при алкоголизме (путём кетаминовой терапии). СПб.: Гиппократ; 1996. 95 с.

[11] Krupitsky E, Burakov A, Romanova T et al. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23:273–283. DOI: 10.1016/s0740-5472(02)00275-1.

[12] Krupitsky E., Burakov A., Romanova T. et al. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up // J. Subst. Abuse Treat. 2002. Vol. 23. P. 273–283. DOI: 10.1016/s0740-5472(02)00275-1.

[13] Krupitsky EM. Ketamine psychedelic therapy (KPT) of alcoholism and neurosis. Multidisciplinary Association for Psychedelic Studies Newsletter. 1992;3:24–28.

[14] Krupitsky E.M. Ketamine psychedelic therapy (KPT) of alcoholism and neurosis // Multidisciplinary Association for Psychedelic Studies Newsletter. 1992. Vol. 3. P. 24–28.

[15] Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. J Psychoactive Drugs. 1997;29:165–183. DOI: 10.1080/02791072.1997.10400185.

[16] Krupitsky E.M., Grinenko A.Y. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research // J. Psychoactive Drugs 1997. Vol. 29. P. 165–183. DOI: 10.1080/02791072.1997.10400185.

[17] Krupitsky EM, Grinenko AYa, Berkaliev TN et al. The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method. Alcoholism Treatment Quarterly. 1992;9:99–105.

[18] Krupitsky E.M., Grinenko A.Ya., Berkaliev T.N. et al. The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method // Alcoholism Treatment Quarterly. 1992. Vol. 9. P. 99–105.

[19] Carhart-Harris RL. How do psychedelics work? Curr Opin Psychiatry. 2019;32(1):16–21. DOI: 10.1097/YCO.0000000000000467.

[20] Carhart-Harris R.L. How do psychedelics work? // Curr. Opin. Psychiatry. 2019. Vol. 32. N. 1. P. 16–21. DOI: 10.1097/YCO.0000000000000467.

[21] Dakwar E, Anerella C, Hart CL et al. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–157. DOI: 10.1016/j.drugalcdep.2013.12.019.

[22] Dakwar E., Anerella C., Hart C.L. et al. Therapeutic infusions of ketamine: Do the psychoactive effects matter? // Drug Alcohol. Depend. 2014. Vol. 136. P. 153–157. DOI: 10.1016/j.drugalcdep.2013.12.019.

[23] Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol. 2015;29(3):241–253. DOI: 10.1016/j.drugalcdep.2013.12.019.

[24] Majić T., Schmidt T.T., Gallinat J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? // J. Psychopharmacol. 2015. Vol. 29. N. 3. P. 241–253. DOI: 10.1016/j.drugalcdep.2013.12.019.

[25] Mollaahmetoglu OM, Keeler J, Ashbullby KJ et al. “This is something that changed my life”: A qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry. 2021;12:695335. DOI: 10.3389/fpsyt.2021.695335.

[26] Mollaahmetoglu O.M., Keeler J., Ashbullby K.J. et al. “This is something that changed my life”: A qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders // Front. Psychiatry. 2021. Vol. 12. P. 695335. DOI: 10.3389/fpsyt.2021.695335.

[27] Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol. 2021;35(2):150–158. DOI: 10.1177/0269881120970879.

[28] Rothberg R.L., Azhari N., Haug N.A., Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial // J. Psychopharmacol. 2021. Vol. 35. N. 2. P. 150–158. DOI: 10.1177/0269881120970879.

[29] Grof S. My ketamine journeys, or ketamine and the enchantment of other worlds. In: The ketamine papers: Science, therapy, and transformation / Ed. By P. Wolfson, G. Hartelius. Santa Cruz, CA: MAPS; 2016. p. 39–47.

[30] Grof S. My ketamine journeys, or ketamine and the enchantment of other worlds. In: The ketamine papers: Science, therapy, and transformation / Ed. By P. Wolfson, G. Hartelius. Santa Cruz, CA: MAPS; 2016. P. 39–47.

[31] Metzner R. John Lilly and ketamine: Some personal recollections. In: The ketamine papers: Science, therapy, and transformation / Ed. by P. Wolfson, G. Hartelius. Santa Cruz, CA: MAPS; 2016. p. 47–51.

[32] Metzner R. John Lilly and ketamine: Some personal recollections. In: The ketamine papers: Science, therapy, and transformation / Ed. By P. Wolfson, G. Hartelius. Santa Cruz, CA MAPS; 2016. P. 47–51.

[33] Dakwar E, Nunes EV, Hart CL et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270–276. DOI: 10.1016/j.neuropharm.2018.01.005.

[34] Dakwar E., Nunes E.V., Hart C.L. et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study // Neuropharmacology. 2018. Vol. 142. P. 270–276. DOI: 10.1016/j.neuropharm.2018.01.005.

[35] Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology. 2018;1(42):72–82. DOI: 10.1016/j.neuropharm.2018.01.017.

[36] Ivan Ezquerra-Romano I., Lawn W., Krupitsky E., Morgan C.J.A. Ketamine for the treatment of addiction: Evidence and potential mechanisms // Neuropharmacology. 2018. Vol. 1. N. 42. P. 72–82. DOI: 10.1016/j.neuropharm.2018.01.017.

[37] Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 2011;30:22–60. DOI: 10.1159/000324065.

[38] Gardner E.L. Addiction and brain reward and antireward pathways // Adv. Psychosom. Med. 2011. Vol. 30. P. 22–60. DOI: 10.1159/000324065.

[39] Koob GF. Antireward, compulsivity, and addiction: Seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction. Psychopharmacology (Berl). 2017;234(9–10):1315–1332. DOI: 10.1007/s00213-016-4484-6.

[40] Koob G.F. Antireward, compulsivity, and addiction: Seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction // Psychopharmacology (Berl.). 2017. Vol. 234. N. 9–10. P. 1315–1332. DOI: 10.1007/s00213-016-4484-6.

[41] Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: From molecular changes to circuit remodeling. Neuron. 2011;69(4):650–663. DOI: 10.1016/j.neuron.2011.01.017.

[42] Lüscher C., Malenka R.C. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling // Neuron. 2011. Vol. 69. N. 4. P. 650–663. DOI: 10.1016/j.neuron.2011.01.017.

[43] Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. Physiol Rev. 2019;99(4):2115–2140.

[44] Volkow N.D., Michaelides M., Baler R. The neuroscience of drug reward and addiction // Physiol. Rev. 2019. Vol. 99. N. 4. P. 2115–2140.

[45] Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21(11):611–624. DOI: 10.1038/s41583-020-0367-2.

[46] Vollenweider F.X., Preller K.H. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders // Nat. Rev. Neurosci. 2020. Vol. 21. N. 11. P. 611–624. DOI: 10.1038/s41583-020-0367-2.

[47] Gopinath K, Maltbie E, Urushino N et al. Ketamine-induced changes in connectivity of functional brain networks in awake female nonhuman primates: A translational functional imaging model. Psychopharmacology (Berl). 2016;233(21–22):3673–3684. DOI: 10.1007/s00213-016-4401-z.

[48] Gopinath K., Maltbie E., Urushino N. et al. Ketamine-induced changes in connectivity of functional brain networks in awake female nonhuman primates: a translational functional imaging model // Psychopharmacology (Berl.). 2016. Vol. 233. N. 21–22. P. 3673–3684. DOI: 10.1007/s00213-016-4401-z.

[49] Maltbie EA, Gopinath KS, Howell LL. Effects of ketamine treatment on cocaine-induced reinstatement and disruption of functional connectivity in unanesthetized rhesus monkeys. Psychopharmacology (Berl). 2019;236:2105–2118. DOI: 10.1007/s00213-019-05204-4.

[50] Maltbie E.A., Gopinath K.S., Howell L.L. Effects of ketamine treatment on cocaine-induced reinstatement and disruption of functional connectivity in unanesthetized rhesus monkeys // Psychopharmacology (Berl.). 2019. Vol. 236. P. 2105–2118. DOI: 10.1007/s00213-019-05204-4.

[51] Federalnyye klinicheskiye rekomendatsii po diagnostike i lecheniyu sindroma zavisimosti. Opublikovano na sayte Rossiyskogo obshchestva psikhiatrov psychiatr.ru (iyun 2014). https://psychiatr.ru/news/281 (access date: 25.06.2022). (In Russ.)

[52] Федеральные клинические рекомендации по диагностике и лечению синдрома зависимости. Опубликовано на сайте Российского общества психиатров psychiatr.ru (июнь 2014). https://psychiatr.ru/news/281 (дата обращения: 25.06.2022).

[53] Li M, Woelfer M, Colic L et al. Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects. Eur Arch Psychiatry Clin Neurosci. 2020;270(2): 207–216. DOI: 10.1007/s00406-018-0942-y.

[54] Li M., Woelfer M., Colic L. et al. Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects // Eur. Arch. Psychiatry Clin. Neurosci. 2020. Vol. 270. N. 2. P. 207–216. DOI: 10.1007/s00406-018-0942-y.

[55] O’Brien CP, Childress AR, McLellan AT, Ehrman R. A learning model of addiction. Res Publ Assoc Res Nerv Ment Dis. 1992;70:157–177.

[56] O’Brien C.P., Childress A.R., McLellan A.T., Ehrman R. A learning model of addiction // Res. Publ. Assoc. Res. Nerv. Ment. Dis. 1992. Vol. 70. P. 157–177.

[57] Baker TB, Piper ME, McCarthy DE et al. Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychol Rev. 2004;111(1):33–51. DOI: 10.1037/0033-295X.111.1.33.

[58] Baker T.B., Piper M.E., McCarthy D.E. et al. Addiction motivation reformulated: An affective processing model of negative reinforcement // Psychol. Rev. 2004. Vol. 111. N. 1. P. 33–51. DOI: 10.1037/0033-295X.111.1.33.

[59] Spada MM, Caselli G, Nikčević AV, Wells A. Metacognition in addictive behaviors. Addict Behav. 2015;44:9–15. DOI: 10.1016/j.addbeh.2014.08.002.

[60] Spada M.M., Caselli G., Nikčević A.V., Wells A. Metacognition in addictive behaviors // Addict. Behav. 2015. Vol. 44. P. 9–15. DOI: 10.1016/j.addbeh.2014.08.002.

[61] Turel O, Bechara A. A triadic reflective-impulsive-interoceptive awareness model of general and impulsive information system use: Behavioral tests of neuro-cognitive theory. Front Psychol. 2016;7:601. DOI: 10.3389/fpsyg.2016.00601.

[62] Turel O., Bechara A. A triadic reflective-impulsive-interoceptive awareness model of general and impulsive information system use: Behavioral tests of neuro-cognitive theory // Front. Psychol. 2016. Vol. 7. P. 601. DOI: 10.3389/fpsyg.2016.00601.

[63] Hon T, Das RK, Kamboj SK. The effects of cognitive reappraisal following retrieval-procedures designed to destabilize alcohol memories in high-risk drinkers. Psychopharmacology (Berl). 2016;233: 851–861. DOI: 10.1007/s00213-015-4164-y.

[64] Hon T., Das R.K., Kamboj S.K. The effects of cognitive reappraisal following retrieval-procedures designed to destabilize alcohol memories in high-risk drinkers // Psychopharmacology (Berl.). 2016. Vol. 233. P. 851–861. DOI: 10.1007/s00213-015-4164-y.

[65] Torregrossa MM, Corlett PR, Taylor JR. Aberrant learning and memory in addiction. Neurobiol Learn Mem. 2011;96:609–623. DOI: 10.1016/j.nlm.2011.02.014.

[66] Torregrossa M.M., Corlett P.R., Taylor J.R. Aberrant learning and memory in addiction // Neurobiol. Learn Mem. 2011. Vol. 96. P. 609–623. DOI: 10.1016/j.nlm.2011.02.014.

[67] Taylor JR, Torregrossa MM. Pharmacological disruption of maladaptive memory. Handb Exp Pharmacol. 2015;228:381–415. DOI: 10.1007/978-3-319-16522-6_13.

[68] Taylor J.R., Torregrossa M.M. Pharmacological disruption of maladaptive memory // Handb. Exp. Pharmacol. 2015. Vol. 228. P. 381–415. DOI: 10.1007/978-3-319-16522-6_13.

[69] Torregrossa MM, Taylor JR. Neuroscience of learning and memory for addiction medicine: From habit formation to memory reconsolidation. Prog Brain Res. 2016;223:91–113. DOI: 10.1016/bs.pbr.2015.07.006.

[70] Torregrossa M.M., Taylor J.R. Neuroscience of learning and memory for addiction medicine: From habit formation to memory reconsolidation // Prog. Brain Res. 2016. Vol. 223. P. 91–113. DOI: 10.1016/bs.pbr.2015.07.006.

[71] Bouton ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry. 2002;52(10):976–986. DOI: 10.1016/s0006-3223(02)01546-9.

[72] Bouton M.E. Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction // Biol. Psychiatry. 2002. Vol. 52. N. 10. P. 976–986. DOI: 10.1016/s0006-3223(02)01546-9.

[73] Taujanskaite U, Cahill EN, Milton AL. Targeting drug memory reconsolidation: A neural analysis. Curr Opin Pharm. 2020;56:7–12. DOI: 10.1016/j.coph.2020.08.007.

[74] Taujanskaite U., Cahill E.N., Milton A.L. Targeting drug memory reconsolidation: A neural analysis // Curr. Opin. Pharm. 2020. Vol. 56. P. 7–12. DOI: 10.1016/j.coph.2020.08.007.

[75] Witteman J, Post H, Tarvainen M et al. Cue reactivity and its relation to craving and relapse in alcohol dependence: A combined laboratory and field study. Psychopharmacology (Berl). 2015;232(20):3685–3696. DOI: 10.1007/s00213-015-4027-6.

[76] Witteman J., Post H., Tarvainen M. et al. Cue reactivity and its relation to craving and relapse in alcohol dependence: A combined laboratory and field study // Psychopharmacology (Berl.). 2015. Vol. 232. N. 20. P. 3685–3696. DOI: 10.1007/s00213-015-4027-6.

[77] McGaugh JL. Time-dependent processes in memory storage. Science. 1966;153:1351–1358. DOI: 10.1126/science.153.3742.1351.

[78] McGaugh J.L. Time-dependent processes in memory storage // Science. 1966. Vol. 153. P. 1351–1358. DOI: 10.1126/science.153.3742.1351.

[79] Lewis DJ. Psychobiology of active and inactive memory. Psychol Bull. 1979;86:1054–1083.

[80] Lewis D.J. Psychobiology of active and inactive memory // Psychol. Bull. 1979. Vol. 86. P. 1054–1083.

[81] Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature. 2000;406:722–726. DOI: 10.1038/35021052.

[82] Nader K., Schafe G.E., Le Doux J.E. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval // Nature. 2000. Vol. 406. P. 722–726. DOI: 10.1038/35021052.

[83] Nader K, Hardt O. A single standard for memory: The case for reconsolidation. Nat Rev Neurosci. 2009;10(3):224–234. DOI: 10.1038/nrn2590.

[84] Nader K., Hardt O. A single standard for memory: the case for reconsolidation // Nat. Rev. Neurosci. 2009. Vol. 10. N. 3. P. 224–234. DOI: 10.1038/nrn2590.

[85] Elsey JWB, Kindt M. Tackling maladaptive memories through reconsolidation: From neural to clinical science. Neurobiol Learn Mem. 2017;142(Pt A):108–117. DOI: 10.1016/j.nlm.2017.03.007.

[86] Elsey J.W.B., Kindt M. Tackling maladaptive memories through reconsolidation: From neural to clinical science // Neurobiol. Learn Mem. 2017. Vol. 142. Pt. A. P. 108–117. DOI: 10.1016/j.nlm.2017.03.007.

[87] Kindt M, van Emmerik A. New avenues for treating emotional memory disorders: Towards a reconsolidation intervention for posttraumatic stress disorder. Ther Adv Psychopharmacol. 2016;6(4):283–295. DOI: 10.1177/2045125316644541.

[88] Kindt M., van Emmerik A. New avenues for treating emotional memory disorders: Towards a reconsolidation intervention for posttraumatic stress disorder // Ther. Adv. Psychopharmacol. 2016. Vol. 6. N. 4. P. 283–295. DOI: 10.1177/2045125316644541.

[89] Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories after their reactivation: Role of beta adrenergic receptors. J Neurosci Off J Soc Neurosci. 1999;19:6623–6628. DOI: 10.1523/JNEUROSCI.19-15-06623.

[90] Przybyslawski J., Roullet P., Sara S.J. Attenuation of emotional and nonemotional memories after their reactivation: Role of beta adrenergic receptors // J. Neurosci. Off. J. Soc. Neurosci. 1999. Vol. 19 . P. 6623–6628. DOI: 10.1523/JNEUROSCI.19-15-06623.

[91] Von der Goltz C, Vengeliene V, Bilbao A et al. Cue-induced alcohol-seeking behaviour is reduced by disrupting the reconsolidation of alcohol-related memories. Psychopharmacology. 2009;205:389–397. DOI: 10.1007/s00213-009-1544-1.

[92] Von der Goltz C., Vengeliene V., Bilbao A. et al. Cue-induced alcohol-seeking behaviour is reduced by disrupting the reconsolidation of alcohol-related memories // Psychopharmacology. 2009. Vol. 205 . P. 389–397. DOI: 10.1007/s00213-009-1544-1.

[93] Lee JL, Nader K, Schiller D. An update on memory reconsolidation updating. Trends Cogn Sci. 2017;21(7):531–545. DOI: 10.1016/j.tics.2017.04.006.

[94] Lee J.L., Nader K., Schiller D. An update on memory reconsolidation updating // Trends Cogn. Sci. 2017. Vol. 21. N. 7. P. 531–545. DOI: 10.1016/j.tics.2017.04.006.

[95] Chen L, Yan H, Wang Y et al. The mechanisms and boundary conditions of drug memory reconsolidation. Front Neurosci. 2021;15:717956. DOI: 10.3389/fnins.2021.717956.

[96] Chen L., Yan H., Wang Y. et al. The mechanisms and boundary conditions of drug memory reconsolidation // Front. Neurosci. 2021. Vol. 15. P. 717956. DOI: 10.3389/fnins.2021.717956.

[97] Exton-McGuinness MT, Milton AL. Reconsolidation blockade for the treatment of addiction: Challenges, new targets, and opportunities. Learn Mem. 2018;25(9):492–500. DOI: 10.1101/lm.046771.117.

[98] Exton-McGuinness M.T., Milton A.L. Reconsolidation blockade for the treatment of addiction: Challenges, new targets, and opportunities // Learn Mem. 2018. Vol. 25. N. 9. P. 492–500. DOI: 10.1101/lm.046771.117.

[99] Lee JL. Reconsolidation: maintaining memory relevance. Trends Neurosci. 2009;32(8):413–420. DOI: 10.1016/j.tins.2009.05.002.

[100] Lee J.L. Reconsolidation: maintaining memory relevance // Trends Neurosci. 2009. Vol. 32. N. 8. P. 413–420. DOI: 10.1016/j.tins.2009.05.002.

[101] Schwabe L, Karim Nader K, Pruessner J. Reconsolidation of human memory: Brain mechanisms and clinical relevance. Biol Psychiatry. 2014;76:274–280. DOI: 10.1016/j.biopsych.2014.03.008.

[102] Schwabe L., Karim Nader K., Pruessner J. Reconsolidation of human memory: Brain mechanisms and clinical relevance // Biol. Psychiatry. 2014. Vol. 76. P. 274–280. DOI: 10.1016/j.biopsych.2014.03.008.

[103] Das RK, Gale G, Walsh K et al. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun. 2019;10(1):5187. DOI: 10.1038/s41467-019-13162-w.

[104] Das R.K., Gale G., Walsh K. et al. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories // Nat. Commun. 2019. Vol. 10. N. 1. P. 5187. DOI: 10.1038/s41467-019-13162-w.

[105] Barak S, Goltseker K. Targeting the reconsolidation of licit drug memories to prevent relapse: Focus on alcohol and nicotine. Int J Mol Sci. 2021;22(8):4090. DOI: 10.3390/ijms22084090.

[106] Barak S., Goltseker K. Targeting the reconsolidation of licit drug memories to prevent relapse: Focus on alcohol and nicotine // Int. J. Mol. Sci. 2021. Vol. 22. N. 8. P. 4090. DOI: 10.3390/ijms22084090.

[107] Dunbar AB, Taylor JR. Reconsolidation and psychopathology: Moving towards reconsolidation-based treatments. Neurobiol Learn Mem. 2017;142:162–171. DOI: 10.1016/j.nlm.2016.11.005.

[108] Dunbar A.B., Taylor J.R. Reconsolidation and psychopathology: Moving towards reconsolidation-based treatments // Neurobiol. Learn. Mem. 2017. Vol. 142. P. 162–171. DOI: 10.1016/j.nlm.2016.11.005.

[109] Milton AL. Drink, drugs and disruption: memory manipulation for the treatment of addiction. Curr Opin Neurobiol. 2013;23(4):706–712. DOI: 10.1016/j.conb.2012.11.008.

[110] Milton A.L. Drink, drugs and disruption: Memory manipulation for the treatment of addiction // Curr. Opin. Neurobiol. 2013. Vol. 23. N. 4. P. 706–712. DOI: 10.1016/j.conb.2012.11.008.

[111] Phelps EA, Hofmann SG. Memory editing from science fiction to clinical practice. Nature. 2019;572:43–50. DOI: 10.1038/s41586-019-1433-7.

[112] Phelps E.A., Hofmann S.G. Memory editing from science fiction to clinical practice // Nature. 2019. Vol. 572. P. 43–50. DOI: 10.1038/s41586-019-1433-7.

[113] Olson DE. Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508. DOI: 10.1177/1179069518800508.

[114] Olson D.E. Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics // J. Exp. Neurosci. 2018. Vol. 12. P. 1179069518800508. DOI: 10.1177/1179069518800508.

[115] Bruel-Jungerman E, Davis S, Laroche S. Brain plasticity mechanisms and memory: A party of four. Neuroscientist. 2007;13(5):492–505. DOI: 10.1177/1073858407302725.

[116] Bruel-Jungerman E., Davis S., Laroche S. Brain plasticity mechanisms and memory: A party of four // Neuroscientist. 2007. Vol. 13. N. 5. P. 492–505. DOI: 10.1177/1073858407302725.

[117] Peters J, Olson DE. Engineering safer psychedelics for treating addiction. Neurosci Insights. 2021;16:26331055211033847. DOI: 10.1177/26331055211033847.

[118] Peters J., Olson D.E. Engineering safer psychedelics for treating addiction // Neurosci. Insights. 2021. Vol. 16. P. 26331055211033847. DOI: 10.1177/26331055211033847.

[119] Krupitskiy EM, Paley AI, Berkaliyev TN. Psikhodelicheskaya psikhoterapiya s primeneniyem ketamina. Konsultativnaya psikhologiya i psikhoterapiya. 1993;2(2):103–130.

[120] Крупицкий Е.М. Палей А.И., Беркалиев Т.Н. и др. Психоделическая психотерапия с применением кетамина // Консультативная психология и психотерапия. 1993. Т. 2. №2. С. 103–130.

[121] Azhari N, Hu H, O’Malley KY et al. Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study. Am J Drug Alcohol Abuse. 2021;47(1):92–97. DOI: 10.1080/00952990.2020.1808982.

[122] Azhari N., Hu H., O’Malley K.Y. et al. Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study // Am. J. Drug Alcohol. Abuse. 2021. Vol. 47. N. 1. P. 92–97. DOI: 10.1080/00952990.2020.1808982.

[123] Dakwar E, Levin F, Hart CL et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–133. DOI: 10.1176/appi.ajp.2019.19070684.

[124] Dakwar E., Levin F., Hart C.L. et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial // Am. J. Psychiatry. 2020. Vol. 177. N. 2. P. 125–133. DOI: 10.1176/appi.ajp.2019.19070684.

[125] Dakwar E, Nunes EV, Hart CL et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized controlled trial. Am J Psychiatry. 2019;176(11):923–930. DOI: 10.1176/appi.ajp.2019.18101123.

[126] Dakwar E., Nunes E.V., Hart C.L. et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized controlled trial // Am. J. Psychiatry. 2019. Vol. 176.N. 11. P. 923–930. DOI: 10.1176/appi.ajp.2019.18101123

[127] Xue YX, Luo YX, Wu P et al. A memory retrieval-extinction procedure to prevent drug craving and relapse. Science. 2012;336:241–245. DOI: 10.1126/science.1215070.

[128] Xue Y.X., Luo Y.X., Wu P. et al. A memory retrieval-extinction procedure to prevent drug craving and relapse // Science. 2012. Vol. 336. P. 241–245. DOI: 10.1126/science.1215070.

[129] Ramirez-Castillo D, Garcia-Roda C, Guell F et al. Frustration tolerance and personality traits in patients with substance use disorders. Front Psychiatry. 2019;10:421. DOI: 10.3389/fpsyt.2019.00421.

[130] Ramirez-Castillo D., Garcia-Roda C., Guell F. et al. Frustration tolerance and personality traits in patients with substance use disorders // Front. Psychiatry. 2019. Vol. 10. P. 421. DOI: 10.3389/fpsyt.2019.00421.

[131] Kraguljac NV, Frölich MA, Tran S et al. Ketamine modulates hippocampal neurochemistry and functional connectivity: A combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers. Mol Psychiatry. 2017;22:562–569. DOI: 10.1038/mp.2016.122.

[132] Kraguljac N.V., Frölich M.A., Tran S. et al. Ketamine modulates hippocampal neurochemistry and functional connectivity: A combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers // Mol. Psychiatry. 2017. Vol. 22. P. 562–569. DOI: 10.1038/mp.2016.122.

[133] Lehmann M, Seifritz E, Henning A et al. Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network. Soc Cogn Affect Neurosci. 2016;11:1227–1235. DOI: 10.1093/scan/nsw034.

[134] Lehmann M., Seifritz E., Henning A. et al. Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network // Soc. Cogn. Affect Neurosci. 2016. Vol. 11. P. 1227–1235. DOI: 10.1093/scan/nsw034.

[135] Cogan ES, Shapses MA, Robinson TE, Tronson NC. Disrupting reconsolidation: memory erasure or blunting of emotional/motivational value? Neuropsychopharmacology. 2019;44(2):399–407. DOI: 10.1038/s41386-018-0082-0.

[136] Cogan E.S., Shapses M.A., Robinson T.E., Tronson N.C. Disrupting reconsolidation: Memory erasure or blunting of emotional/motivational value? // Neuropsychopharmacology. 2019. Vol. 44. N. 2. P. 399-407. DOI: 10.1038/s41386-018-0082-0.

[137] Jobes ML, Aharonovich E, Epstein DH et al. Effects of prereactivation propranolol on cocaine craving elicited by imagery script/cue sets in opioid-dependent polydrug users: A randomized study. J Addict Med. 2015;9(6):491–498. DOI: 10.1097/ADM.0000000000000169.

[138] Jobes M.L., Aharonovich E., Epstein D.H. et al. Effects of prereactivation propranolol on cocaine craving elicited by imagery script/cue sets in opioid-dependent polydrug users: a randomized study // J. Addict. Med. 2015. Vol. 9. N. 6. P. 491–498. DOI: 10.1097/ADM.0000000000000169.

[139] Treanor M, Brown LA, Rissman J, Craske MG. Can memories of traumatic experiences or addiction be erased or modified? A critical review of research on the disruption of memory reconsolidation and its applications. Perspect Psychol Sci. 2017;12:290–305. DOI: 10.1177/1745691616664725.

[140] Treanor M., Brown L.A., Rissman J., Craske M.G. Can memories of traumatic experiences or addiction be erased or modified? A critical review of research on the disruption of memory reconsolidation and its applications // Perspect. Psychol. Sci. 2017. Vol. 12. P. 290–305. DOI: 10.1177/1745691616664725.

[141] Copersino ML. Cognitive mechanisms and therapeutic targets of addiction. Curr Opin Behav Sci. 2017;13:91–98. DOI: 10.1016/j.cobeha.2016.11.005.

[142] Copersino M.L. Cognitive mechanisms and therapeutic targets of addiction // Curr. Opin. Behav. Sci. 2017. Vol. 13. P. 91–98. DOI: 10.1016/j.cobeha.2016.11.005.

[143] Short B, Fong J, Galvez V et al. Side-effects associated with ketamine use in depression: A systematic review. Lancet Psychiatry. 2018;5:65–78. DOI: 10.1016/S2215-0366(17)30272-9.

[144] Short B., Fong J., Galvez V. et al. Side-effects associated with ketamine use in depression: a systematic review // Lancet Psychiatry. 2018. Vol. 5. P. 65–78. DOI: 10.1016/S2215-0366(17)30272-9.

RIGHTS & PERMISSIONS

Eco-Vector